This study is in progress, not accepting new patients
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Summary
- Eligibility
- for females ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Hope Rugo
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Hope Rugo
Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Dana-Farber Cancer Institute
- ID
- NCT00542451
- Phase
- Phase 2 Breast Cancer Research Study
- Study Type
- Interventional
- Participants
- At least 420 people participating
- Last Updated